Abstract
For the first time in 50 years new oral anticoagulants of proven efficacy and with acceptable safety profiles are available for patients with atrial fibrillation and venous thromboembolism. Here is a brief overview of the benefits and possible disadvantages of using these drugs.
Get full access to this article
View all access options for this article.
References
1.
Keeling
D
Baglin
T
Tait
C
British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin, fourth edition. Br J Haematol 2011 ; 154 :311 –24 . http://dx.doi.org/10.1111/j.1365-2141.2011.08753.x
2.
Ghanny
S
Crowther
M.
Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013 ; 20 :430 –6 . http://dx.doi.org/10.1097/MOH.0b013e328363c170
3.
Baglin
T
Keeling
D
Kitchen
S.
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012 ; 159 :427 –9 . http://dx.doi.org/10.1111/bjh.12052
